Conquering PROTAC molecular design and drugability.

Area of Science:

• Biochemistry
• Pharmacology
• Medicinal Chemistry

Background:

• Proteolysis-targeting chimeras (PROTACs) offer a novel therapeutic strategy by inducing targeted protein degradation.
• They overcome limitations of traditional inhibitors and target previously undruggable proteins.
• PROTACs represent a paradigm shift in drug discovery, moving beyond simple inhibition to degradation.

Purpose of the Study:

• To explore advancements in PROTAC molecular design, including ligand discovery, E3 ligase recruitment, and ternary complex optimization.
• To highlight emerging PROTAC technologies and their potential to enhance precision and reduce toxicity.
• To discuss the clinical success and expanding therapeutic applications of PROTACs.

Main Methods:

• Integration of AI-driven modeling, fragment-based drug discovery (FBDD), and structure-based drug discovery (SBDD) to accelerate PROTAC development.
• Development of novel PROTAC modalities like PHOTACs, hypoxia-responsive systems, and antibody-PROTACs (Ab-PROTACs).
• Analysis of clinical trial data for PROTACs in oncology and exploration of applications in other disease areas.

Main Results:

• PROTACs demonstrate significant clinical efficacy, with examples like ARV-110 for castration-resistant prostate cancer and ARV-471 for breast cancer.
• Emerging PROTAC technologies show promise in improving targeting specificity and minimizing off-target effects.
• PROTACs are proving versatile, with expanding applications in neurodegenerative diseases and rare conditions.

Conclusions:

• PROTACs are a versatile and powerful therapeutic modality with the potential to revolutionize precision medicine.
• Continued advancements in molecular design, drugability, and addressing pharmacokinetic and safety challenges will drive their clinical impact.
• PROTACs are expected to yield transformative therapies for a wide range of diseases.